By Matthew Perrone
AP Health Writer
WASHINGTON 鈥� Federal officials are working to move critical hospital supplies out of the path of , which is threatening another manufacturer of IV fluids even as hospitals nationwide are still reeling from disruptions caused by at a large factory in North Carolina.
Medical manufacturer B. Braun Medical said Wednesday it is working with U.S. health authorities to move its inventory of IV bags to a secure facility away from its plant in Daytona Beach, Florida, which it closed ahead of the storm.
The company expects to resume manufacturing and shipping operations Friday morning, company spokesperson Allison Longenhagen said in an email.
Braun is one of several IV producers that have been tapped to boost supplies after Baxter International鈥檚 North Carolina plant was damaged; the plant is responsible for about 60% of the country鈥檚 supply of sterile intravenous, or IV, fluids.
U.S. hospitals use more than 2 million IV bags daily to keep patients hydrated and deliver medicines. But the fallout from a couple of weeks ago forced some hospitals to begin conserving supplies.
Experts who have been tracking the disruptions were encouraged by the news from Florida.
鈥淏axter was caught off guard, but in this case, B. Braun had advance notice and was able to move all of their supply out of harm鈥檚 way,鈥� said Mike Ganio, who studies drug shortages for the American Society of Health-System Pharmacists. 鈥淎nything that鈥檚 already been produced is out of the area and not susceptible to damage.鈥�
This week, the American Hospital Association called on the Biden administration to take additional steps to ease the shortage, including declaring a national emergency and invoking defense production authorities to compel private companies to prioritize IV production.
U.S. Health Secretary Xavier Becerra said in a that the government is 鈥渄oing all we can during this supply chain disruption,鈥� but did not reference the government鈥檚 emergency powers.
Becerra also said his department is considering other steps, including temporary imports of foreign supplies, extending expiration dates on existing IV products and identifying other U.S. plants that can help boost production.
In recent years the U.S. government has used similar steps to address a and earlier caused by COVID-19.
In a separate email, Food and Drug Administration officials noted that a number of IV fluids, including saline solution, were already on the agency鈥檚 drug shortage list before Hurricane Helene. In such cases, hospitals and specialty pharmacies are permitted to compound their own formulations of the scarce supplies to meet patient needs.
Still, Ganio said FDA could ease regulations to speed the monthslong process required for large compounding pharmacies to begin making new products, adding: 鈥淚n order for it to be helpful in the near term, that timeline needs to be shortened.鈥�